|

GT719 Injection Clinical Trials

2 actively recruiting trials

Pipeline

Early 1: 1Phase 1/2: 1

Top Sponsors

  • Grit Biotechnology2

Indications

  • Hematological Malignancy (Leukemia- Lymphoma)2
  • Cancer2

Other2 trials

A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in Adult Participants With Relapsed/Refractory CD19-positive B-cell Malignant Hematological Tumors
Early 1
GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.